Biotech Hot Stock: CURR Expands Highly Valuable Medication Patent Portfolio
by Phillip Fleck Anand Systems Inc Launches, Asi Frontdesk, The NewØ Innovative Medication Development & Enhancement
Company.
Ø Patents for Extraction, Concentration &
Processing of Specialized Medicinal Compounds.
Ø New
Marketing to Mexico in Collaboration with Factoria Bogar Subsidiary.
Ø Balance Sheet Strengthened by $1.4 Million from
June Warrant Exercise.
Ø New Oral Thin Film Products for High Value Male
Dysfunction Market.
On June 3rd CURR,
an innovative medication development and enhancement company announced a
collaboration with PMI, a subsidiary of Factoria
Bogar in Guadalajara,
Mexico. PMI will have access to the CURR bio-product platform, CUREform™ for its medication formulation, and become
its distribution partner in Mexico for CURR wellness products, such as
its vitamin D, sleep and specialized botanical extract products.
The CURR weekly
vitamin D product provides 50,000 IU of vitamin D3 to reduce the risk of
infections. CURR sleep strips contain a soothing blend of melatonin,
naturally occurring amino acids and beneficial vitamins that promote
fast-acting, balanced sleep patterns for a deep, restful slumber and a
rejuvenated awakening.
The PMI collaboration will
include several development initiatives with its proprietary prebiotic product
from Agave in combination with special botanical extracts that leverage the CURR
CUREform™ novel delivery platform for treatment of multiple GI indications. Patient
studies are planned for Mexico to improve medication efficacy with CURR extracts
and prebiotics.
Ø Exercise of Warrants for Cash Proceeds of
Approximately $1.4 Million and Completion of Earn Out Related to 2019
Acquisition
On June 9th CURR
announced it strengthened its balance sheet with the receipt of $1.4 million in
cash from the exercise of warrants to purchase 708,467 shares of CURR
common stock held by stockholders of Chemistry Holdings, Inc. at a reduced
exercise price of $2.00 per share. The warrant exercise is part of the
completion of all earn-out arrangements and obligations related to the CURR
acquisition of Chemistry Holdings on May 14, 2019.
Additionally, on June 16th
CURR named Jonathan Berlent, to the position of Chief Business Officer.
Mr. Berlent will be responsible for corporate strategy, sourcing and executing
business development opportunities and will serve as a member of the company’s
Executive Management Committee. Mr. Berlent is an accomplished business growth
executive with more than 25 years of private and public company experience
focused on strategic partnerships and building businesses seeking to own
end-to-end market verticals. He has led successful strategic business
initiatives across the pharmaceutical, healthcare, life sciences and health
& wellness industries, with particular focus on CBD and cannabis, as well
as diseases of the central nervous system, or CNS.
Ø New Patents Issued on Key Therapeutics for
Infectious Diseases
On April 21st CURR
announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. The
patents represent an expansion of the existing CURR “product by process”
patents for obtaining multiple unique concentrates using super critical fluid
extraction (SCFE). These include concentrates which have shown promising
therapeutic activity in animal studies in areas such as inflammatory bowel
disease, cancer and infectious diseases.
Additionally, CURR is
granting equipment manufacturers, processing companies and medicine developers
licenses to its portfolio of issued and pending process and composition patents
for isolating specific botanical compounds using an advanced SCFE technology
utilizing carbon dioxide as the solvent. While the patents cover the
incorporation of extracts into multiple dosage forms, CURR has retained
all rights to applying these methods in oral thin films.
The two new CURR
patents cover the extraction and purification of specialized plant material, as
well as subsequent processing of extracts for medication formulations. This
extraction and fractioning of bioactive molecules allows for the integration of
molecules into dosage forms.
Ø New Applications in the Multi-Billion Dollar Male
Dysfunction Market
This news follows up on a CURR
announcement of March 17th which detailed the allowance of Chinese
Patent No. ZL201480039313.6 regarding the loading of high amounts of active
medicine on an oral thin film using its proprietary delivery systems. This new
patent includes the company’s lead product, CUREfilm
Blue™, a soluble thin film for oral administration of sildenafil citrate
to treat male dysfunction (ED) in China.
The ED market is expected to
reach USD $6.5 billion at a 6% compound annual growth rate
by 2025, according to QYResearch. The
report points out that the Asia Pacific market will be one of the fastest
growing markets for ED medicine. Sildenafil is leading the ED market
worldwide with more than half of all global sales.
The CURR ED patent
covers methods of preparing edible thin films that can deliver high doses of
active ingredients that are encapsulated using lipids to form micelles or
liposomes. This enables CURR to differentiate its oral thin film product
from sildenafil oral soluble films.
For more Information visit
the CURR company website at: https://www.curepharmaceutical.com/
###
Sponsor Ads
Created on Jul 9th 2020 00:27. Viewed 272 times.